For decades, migraine prevention relied on nonspecific, off-label drugs, often lacking large-scale clinical trials to confirm their efficacy, safety, or tolerability.1-3 This has resulted in high discontinuation rates.2,3 However, the introduction of calcitonin gene-related peptide (CGRP) pathway-ta

Migraine exhibits a 2-3 fold higher prevalence in women compared to men.1 Among females, migraines are typically of longer duration, more debilitating, and more likely to recur post-initial treatment.1 Studies have found that triptans were ineffective in up to 40% of migraine attacks.1  Rimegepant,